Introduction
Surgical cytoreduction of advanced-stage ovarian cancer has long been considered an important tenet of effective management of this disease. Although the sequence of chemotherapy and surgical intervention is debated, there is broad consensus that integration of the two modalities represents the best initial strategy for women with metastatic disease. Retrospective, case-cohort and meta-analysis reports have demonstrated a strong prognostic link between degree of postoperative residual disease and objective clinical and pathological complete response rates, progression-free survival (PFS) and overall survival. 1 This relationship is most discriminative between patients with no detectable residual disease, so-called R0 resection, and those with any measure of residual disease. 2, 3 Reports show incremental survival benefits among patients with residual disease volumes under 1 cm; however, most studies report limited benefit from a debulking effort if the residual disease cannot be reduced to less than 1 cm. 4 As a consequence of these observations, the metric for 'optimal' surgical cytoreduction was defined as no tumour nodules greater than 1 cm. 2, 3, 5, 6 However, on the basis of recent data, 7 we feel that a strong case can be made for raising the bar for optimal cytoreduction to R0, given the robust prognostic value, lower prevalence, and unambiguous assignment associated with this approach after surgery. Moreover, a personalized surgical approach is desirable to enable rational decision-making with regard to the timing of surgery. We provide a brief overview of the historical progression of primary cytoreduction and definitions of 'optimal' residual disease, highlight current gaps in our knowledge in this regard, and present logical suggestions for personalized surgical approaches for women with advanced-stage ovarian cancer.
Definition of optimal cytoreduction
Primary cytoreduction Surgical outcome among patients with advanced-stage ovarian cancer is defined by the amount of postoperative residual tumour. A complete gross resection (R0) is achieved if no macroscopic residual tumour remains. Following surgery, if any visible tumour remains it is classified according to the largest residual diameter. Historically, operations resulting in residual tumour up to 2 cm in diameter have been classified as 'optimal' whereas those resulting in any larger residual tumour being defined as 'suboptimal' . 8 A single-institution observational study was one of the first studies in patients with advanced-stage ovarian cancer to demonstrate a survival advantage with cytoreduction, in which survival was inversely correlated with residual tumour size. 2 Several retrospective studies have validated the relationship between postoperative residual tumour and clinical outcomes, despite multiple different 'optimal' resection criteria. As a result, these studies have firmly established primary cytoreduction followed by platinum-based chemotherapy as the standard management for patients with advanced-stage epithelial ovarian cancer (Table 1) . 3, [5] [6] [7] The definition of 'optimal' cytoreduction, however, continues to evolve and remains a critical focus of ongoing clinical investigation.
Studies from the Gynecologic Oncology Group (GOG), GOG 52 and GOG 97, 9, 10 have examined the correlation between max imal diameter of residual disease after primary cytoreduction and patient survival, with unsurprisingly the longest survival noted among those with no macro scopic residual disease. After controlling for other prognostic variables, the maximal diameter of residual disease was found to be an indepen dent predictor of overall survival; those patients with no residual disease had a 5-year survival rate of 60% compared with 35% and <20%, respectively, for those with 0.1-1 cm or 1-2 cm residual disease. 9, 10 Data from meta-analyses have suggested a close association between maximal cytoreduction and overall survival, with each incremental 10% increase in the degree of cyto reduction associ ated with a concomitant 5.5% increase in median survival of the cohort. 11 However,
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the relationship is probably nonlinear and complicated further by the fact that definitions of surgical outcome are not binary and are subjective: 12 what one surgeon classifies as optimal (<1 cm) might be classified differently by another surgeon as complete resection of all visible disease (R0)-the most objective classifier of surgical success. In addition, plaque-like disease in the pelvis or the diaphragm surfaces is difficult to quantify because it could represent a thinly coated coalition of several subcentimetre nodules ( Figure 1) .
Critics of these original reports on the impact of residual disease on patient survival regard inherent tumour biology as an important aspect of the observed differences. For example, many of the initial studies pre-date the taxane era. 9 Contemporary studies have sought to analyse the impact of complete gross resection on patient survival. In such studies, patients with R0 resection had substantially improved median survival compared with those with any residual disease. 6 Even in patients with the most-extensive disease, performance of radical surgery and status of residual disease were the only independent prognostic factors associated with 5-year disease-specific survival. 6 The quality of surgery by individual surgeons has an impact on outcome because substantial improvements in median overall survival were observed among patients treated by surgeons who frequently used radical procedures compared with those who did not. 13, 14 Furthermore, a 30% reduction in recurrence risk after primary treatment is associated with institutions that perform complex surgeries in more than 25% of patients. 13 Surgeons at institutions that have successfully incorporated more radical resection to improve rates of complete or optimal cyto reduction have achieved acceptable outcomes without serious morbidity and/or mortality. For example, Chi 16 Given the survival benefit observed with R0 resection, patients with advanced-stage ovarian cancer in whom R0 resection is unlikely to be achieved should be considered for neo adjuvant chemotherapy (NACT) f ollowed by interval cytoreductive surgery.
Neoadjuvant chemotherapy and surgery Administration of NACT followed by interval cytoreductive surgery offers an alternate approach to the primary management of advanced-stage epithelial ovarian cancer, and one that has been the topic of much investigation. Data from retrospective meta-analyses indicate that NACT was associated with a worse outcome compared with primary debulking. 17 More recently, however, the results of two randomized, controlled, prospective trials conducted by the European Organisation for Research and Treatment of Cancer (EORTC) and the Medical Research Council (MRC) Clinical Trials Unit have investigated the potential benefit of NACT compared with primary cytoreduction among patients with stage III or stage IV ovarian cancer. 18, 19 In both studies, patients were randomly assigned to either primary cytoreductive surgery or neoadjuvant chemotherapy. Although no significant difference in overall survival (the primary outcome) was observed between the two cohorts of patients, a higher rate of R0 resection was achieved among those patients who underwent NACT. Improved survival was noted among those who underwent R0 resection at primary (median survival 45.0 months versus 32.4 months for <1 cm residual disease, and 25.7 months for >1 cm postoperative disease; P <0.0002) or interval surgery (38.2 months versus 27.0 months and 25.5 months for <1 cm and >1 cm residual disease, respectively; P = 0.56). In a post-hoc multivariate analysis, absence of residual tumour was noted to be the strongest independent prognostic variable in predicting overall survival Nature Reviews | Clinical Oncology Figure 1 | Plaque-like disease involving the diaphragm. This disease burden is difficult to quantify as it might represent a thinly coated coalition of several sub-centimetre nodules. PERSPECTIVES (P <0.001). 18 Furthermore, subgroup analyses demonstrated improved overall survival among patients who underwent R0 resection, with no difference in overall survival when comparing surgical outcome in upfront or interval settings. Critics of these studies have raised concerns about the absolute number of patients who underwent 'optimal' cytoreduction at the participating institutions; a retrospective study has demonstrated superior survival in the primary cytoreduction cohort with an 'optimal' cytoreduction rate of 71% (compared with 41.6% in the EORTC study). 20 Although administration of NACT can yield increased rates of R0 resection, the equivalence of such surgical outcome in the primary and interval s ettings remains to be demonstrated.
Diagnostic methods for cytoreduction
Despite the collective data demonstrating the survival advantage with 'optimal' or R0 resection at the time of ovarian cancer cyto reduction, meta-analyses of data from patient cohorts across the USA have demonstrated an optimal cytoreduction (variably defined) rate of 42%. 4, 11 In fact, most patients who undergo cytoreductive surgery will be left with visible disease and will not experience the same magnitude of survival advantage as those who achieve complete resection, but will nevertheless experience morbidity resulting from an extensive surgical procedure. Reasons for incomplete cytoreduction are multifactorial and can be surgeon-related and disease-specific. 21 Surveys of practicing gynaecological oncologists reflect practicepattern variations, and concerns have been raised regarding the safety and benefit of aggressive cyto reduction among patients with medical comorbidities or differences in tumour biology as reasons for offering patients NACT followed by interval cytoreduction. 21, 22 Furthermore, administration of NACT is less robust than the evidence for recommending primary cytoreductive surgery, particularly in the USA, where critics have suggested failure to incorporate upper abdominal surgery and maximal cytoreductive effort is the primary reason for a lack of survival advantage associ ated with primary tumour treatment. 20 These data highlight the need for a much more personalized approach, incorporating accurate predictors of R0 resection. To date, predictive models, such as those described by Bristow and others or Abdallah and colleagues, that utilize clinical parameters, serum markers, and radiographic features or genomic analy ses, respectively, have demonstrated good sensitivity and specificity when evaluated in small cohorts of patients, but these models are not generalizable. Developing an algorithm that identi fies the patients in whom complete gross resection is likely to be achieved at primary surgery would be expected to improve patient s urvival, and this is d iscussed later.
Serum markers

CA-125
Preoperative CA-125 levels have been one of the most-studied parameters for predicting surgical outcome among patients with advanced-stage ovarian cancer. Given that CA-125 levels are found to be elevated in more than 90% of patients 23 and can be a surrogate marker for extent of tumour burden, numerous studies have attempted to identify a threshold level above which optimal surgical resection is not feasible. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [47] [48] [49] Of these studies, many have used a CA-125 cut point of 500 U/ml as a critical value in the analysis of the ability to predict optimal cytoreduction, with varying degrees of success and reproducibility. 24, 25, [28] [29] [30] 32, 33, 35, 36, [47] [48] [49] However, because of evolving surgical practices (that is, the implementation of more radical surgical procedures to achieve optimal cytoreduction), levels of CA-125 have been shown to no longer correlate with surgical outcome. 47 Collectively, studies evaluating the predictive ability of CA-125 have been confounded by variable surgical effort, making it hard to generalize CA-125 cut points for predicting surgical outcomes in broader populations of women with advanced-stage ovarian carcinoma.
CT
CT imaging is the most commonly used modality for the preoperative assessment of patients with advanced-stage ovarian cancer. CT can be used for staging, as well as a tool for monitoring disease recurrence or persistent disease. Several studies have exploited disease characteristics from CT imaging and their predictive ability to estimate surgical success. [38] [39] [40] [41] [42] [43] Of these studies, only three used more contempor ary definitions of optimal cytoreduction (residual disease <1 cm). [40] [41] [42] Each study used a unique set of radiographic features, such as diffuse peritoneal thickening, large volume ascites, or large bowel mesen eric involvement, to determine a score predict ive of suboptimal tumour reductive surgery, which was associated with 100% sensitivity in single institution cohorts of patients. [40] [41] [42] However, attempts to cross validate the results between institutions were largely unsuccessful, probably due to differences in each individual surgeon's ability to use radical surgery to achieve maximal cytoreduction. Collectively, several limitations of studies evaluating CT predictors of surgical outcome exist. These limitations include variability in CT features (including technique and radio logist skill) evaluated, as well as individual surgeons' views on the procedure and its execution, and their skill sets. Moreover, CT imaging is more likely to reveal disease that is clearly unresectable, such as the presence of extraabdominal metastases, making it less useful for predicting R0 resection. CT findings have also been combined with assessment of CA-125 levels and other clinical criteria, such as patient performance status and age, to identify those patients in whom optimal cytoreduction is unlikely to be achieved. 44 In multivariate analysis, three clinical and six radiographic criteria were associated with suboptimal cytoreduction: age >60 years; CA-125 >500 U/ml; American Society of Anesthesiologists (ASA) physical status 3-4; suprarenal lymphadeno pathy >1 cm; diffuse small bowel thickening; or a tumour >1 cm in diameter in the small bowel mesentery; root of the superior mesenteric artery; perisplenic area, or lesser sac. 44 The performance of this pretreatment p redictive value score remain to be validated.
Minimally invasive surgery
In light of the limitations described for serum biomarkers and CT imaging, the primary issue of how best to evaluate the resectability of patients with advancedstage ovarian cancer remains an unmet need. Laparoscopy has been investigated as a means of avoiding cytoreduction, and the potential morbidity associated with a laparo tomy that results in sub optimal residual disease. To test the utility of this approach, 64 patients suspected of having advanced-stage disease have been evaluated with laparoscopy followed by standard laparo tomy. 50 The overall accuracy rate of laparoscopy in assessing optimal cytoreduction (defined as <1 cm) was 90% compared with a corresponding negative predictive value of the clinical-radiological evaluation of 73%; 50 there were no cases in which the judgement of unresectable disease as determined by laparoscopy was changed by laparotomy assessment. 50 Subsequently, a quantitative predictive model based on the pattern of disease (Table 2 ) was tested and validated. 51 Components of the predictive model include evaluation of the degree of peritoneal carcinomatosis, diaphragm disease, mesenteric involvement, the need for potential bowel resection, liver surface involvement, obvious neoplastic involvement of the gastric wall, and omental disease up to the level of the greater curvature of the stomach. 51 Parameters that were present received a score of 2 and parameters that are absent received a score of 0. 51 The additive sum of scores results in a predictive index value (PIV), with a PIV ≥8 resulting in a predictive probability of optimal cytoreduction of 0 suggesting that the patient should be triaged to NACT. 51 In a followup study, 52 patients were prospectively assessed with laparoscopy and the accuracy of predicting optimal cytoreduction by the laparoscopic procedure ranged between 77.3-100%. When comparing survival among those patients triaged to primary cytoreductive surgery after laparo scopic evaluation, those in whom complete gross resection was achieved had the longest survival durations. 53 These results have led to the SCORPION trial, 54 a prospective random ized controlled trial of primary debulk ing surgery versus NACT among those patients with PIV of 8-12.
Knowledge gaps
With the advent of various 'omic' technologies, several investigators have sought to characterize molecular predictors of residual disease at the time of cytoreduction, with varying degrees of success. Molecular predictors of surgical outcome have the advantage of incorporating tumour biology into medical decision-making. Collectively, approaches that incorporate tumour biology were better at predicting incomplete cyto reduction that results in macroscopic residual tumour (sensitivity 82% and positive predictive value 78%). 45 We have used publicly available genomic datasets (The Cancer Genome Atlas [TCGA] and Tothill) to discover candidate genetic markers associ ated with a high likelihood of residual disease. We found that high levels of FABP4 and ADH1B expression in the tumour were associated with a markedly higher risk of residual disease than low levels of these markers. 46 Collectively, studies of molecular predictors demonstrate some progress in the aim of personalizing surgical therapy; however, limitations exist, because external validity remains to be established. Furthermore, compared with clinical predictors that are readily available before surgical intervention, molecular predictors have been based on expression within the tumour and so cannot be assessed preoperatively. Ultimately, both molecular and clinical predictors might become equally useful in different scenarios, but further investigation is warranted. Internal QI consultant ≥8 Nature Reviews | Clinical Oncology Figure 2 | Key features of the MD Anderson Cancer Center, TX, USA, quality improvement programme. All patients deemed appropriate surgical candidates are offered diagnostic laparoscopy for peritoneal disease assessment. Two surgeons independently score the abdomen to determine resectability of disease: patients with a PIV <8 are offered primary cytoreductive surgery; patients with a PIV ≥8 are offered NACT and subsequent interval tumour reductive surgery as indicated. Abbreviations: NACT, neoadjuvant chemotherapy; PIV, predictive index value; QI, quality improvement; TRS, tumour reductive surgery.
Improving quality of surgery
Standardizing medical practice Despite the fact that the residual tumour volume following cytoreductive surgery remains the main prognostic factor that affects clinical outcome among patients with advanced-stage ovarian cancer, marked disparities exist in the definition of 'optimal' resection and rates of R0 cytoreduction among cancer centres within the USA. The reasons for this inconsistency are multifactorial and include differences in surgeon skill and training, suboptimal infrastructure for delivery of highly specialized care, and inability to accurately predict the patients likely to achieve surgical success defined as complete cytoreduction. Data that emphasize the survival advantage imparted on patients who undergo R0 cytoreduction present a unique metric that is clearly measurable and can be exploited to improve the quality of surgical care.
The Anderson Algorithm
To improve the proportion of patients with advanced-stage ovarian cancer undergoing complete cytoreduction, we have introduced a quality improvement programme with the goal of improving rates of R0 resection. This initiative is part of the Women's Cancer Moon Shot Program, 55 a comprehensive multidisciplinary research effort focused on improving survival among patients with high-grade serous ovarian cancer. On the basis of the breadth of data describing the impact of residual disease on patient outcome, we anticipate that increasing rates of R0 resection will result in a reciprocal improvement in both PFS and overall survival. Key features of our quality improvement programme are shown in Figure 2 , and include the following aims. First, all patients with a suspected diagnosis of advanced-stage ovarian cancer will be prospectively screened and their data tracked. Second, surgeons will be educated on the importance of R0 resection, and we have developed a consensus recommendation to offer NACT to those patients in whom complete gross resection is unlikely to be achieved. Third, multidisciplinary assessment of disease distribution, via collaboration with hepato biliary, thoracic, colorectal and urological surgical oncology, will be undertaken when indicated. Fourth, diagnostic laparoscopy for peritoneal disease assessment will be incorporated for all surgically fit patients with suspected advanced-stage ovarian cancer, in order to determine resectability of disease. Fifth, inclusion of a two-surgeon opinion at diagnostic laparoscopy for peritoneal disease assessment will be made to ensure consistent opinion of disease resectability across different surgeons in the same clinical practice, with the availability of a third adjudicating faculty member, if necessary. In addition, weekly quality improvement meetings will be held, and will include adherence to pre-set guidelines and reporting of morbidity and patient outcome. Finally, consensus among all gynaecological oncologists will be met to follow the project's standard o perating procedures for eligible patients.
At the MD Anderson Cancer Center, all patients presenting with presumed advanced-stage (stage III or stage IV) ovarian cancer are considered for a twosurgeon laparoscopic tumour evaluation (The Anderson Algorithm). A validated composite scoring system is used to determine the ability to resect the tumour so no gross residual disease remains:
52 patients with scores <8 will undergo primary cytoreductive surgery; patients with scores ≥8 will receive NACT with subsequent interval tumour reductive surgery. Fresh frozen tumour samples are obtained from the follow ing pre-specified sites: the ovary (or suspected primary); the omentum; and from two additional metastatic sites at the time of primary tumour assessment (diagnostic laparoscopy and/or primary cytoreductive surgery). Following three cycles of NACT, interval cytoreduction is undertaken in all patients who exhibit partial response to induction chemo therapy. For those patients with gross disease, additional fresh tissue from matching sites is obtained to compare with the primary pre-chemotherapy samples for characterization of adaptive changes related to chemo therapy exposure. Several opportunities are provided by this approach: first, the option to proceed with upfront debulking in only those patients in who R0 resection and the reciprocal anticipated survival benefit are most likely to be achieved; second, collection of untreated tumour is possible; third, the time between laparoscopic evaluation and tumour reductive surgery provides an opportunity to evaluate the clinical and molecular impact of novel therapeutic agents among those triaged to primary cytoreductive surgery (that is, 'window of opportunity' trials); and finally, the tumour collected at the time of interval cytoreductive surgery can be evaluated for the impact of novel combinations of neoadjuvant therapeutic agents (Figure 3) . The 'window-of-opportunity' studies offer a unique opportunity to study the effects of novel therapeutics on tumours, in a manner that has never been possible among patients with advancedstage ovarian cancer due to the inability to procure tissue for assessment. By allowing the study of end-tissue effects after exposure to single-agent biological therapy in treatment-naive patients, we anticipate being able to develop b iomarkers of risk and response.
When evaluating the feasibility of this algorithm, we noted significant improvements in rates of complete resection at the 56 In the feasibility phase, no surgical third opinions were required. 56 In addition, a trend towards increased complete resection in patients undergoing NACT was observed (R0 rates of 65% [pre-implementation] versus 100% [post-implementation]; P = 0.15). 56 At the time of this report, no port site metastases and no differences in surgical morbidity have been observed between patients who underwent primary cytoreductive surgery and those who underwent interval surgery after NACT. 56 We anticipate the improvement in R0 resection will translate into improved patient PFS and overall survival. 56 
Conclusions
Survival of patients with advanced-stage ovarian cancer is inversely proportional to the volume of residual disease. Those with no gross residual disease (R0) have the best outcome compared with patients with any visible residual disease. The objective of primary cytoreduction should be complete removal of all macroscopic tumours. Diagnostic laparoscopy enables rapid assessment of extent of peritoneal disease distribution and resectability of disease. Only those patients most amenable to achieve R0 resection should be offered primary cytoreductive surgery, thereby allowing a more rational and personalized surgical approach. Centres should strive to standardize the surgical approach to the treatment of patients with advanced-stage ovarian cancer, with systematic quality improvement initiatives to improve surgical outcomes and patient survival. Future studies regarding the direct impact of surgical cytoreduction among patients with advanced-stage ovarian cancer will help to determine the ideal timing of surgery as well as potential benefits of surgery beyond complete resection and reciprocal i mprovement in survival. 
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